Day One Biopharmaceutical... (DAWN)
| Bid | 7.16 |
| Market Cap | 759.65M |
| Revenue (ttm) | 131.16M |
| Net Income (ttm) | -95.5M |
| EPS (ttm) | -1.02 |
| PE Ratio (ttm) | -7.35 |
| Forward PE | -11.23 |
| Analyst | Buy |
| Ask | 8.18 |
| Volume | 586,770 |
| Avg. Volume (20D) | 1,202,858 |
| Open | 7.86 |
| Previous Close | 7.93 |
| Day's Range | 7.49 - 7.97 |
| 52-Week Range | 6.41 - 17.79 |
| Beta | -1.25 |
About DAWN
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral s...
Analyst Forecast
According to 7 analyst ratings, the average rating for DAWN stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 326.95% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · https://www.marketscreener.com
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer TreatmentThe global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i...
3 weeks ago · seekingalpha.com
Day One Biopharmaceuticals Pullback Is A Potential Buying OpportunityDay One Biopharmaceuticals' Ojemda launched in Q2'24 and generated $57.2M in net product revenues in 2024. Despite reporting continued sales growth so far, DAWN's stock is near 52-week lows, perhaps i...
2 months ago · seekingalpha.com
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call TranscriptDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendi...
